Michele Marin Appointed as New Member of the Italian Board of Directors

Food and Healthcare Press Releases Thursday May 3, 2018 11:42
SAN DANIELE DEL FRIULI, Italy--3 May--PRNewswire/InfoQuest

LimaCorporate has appointed Mr. Michele Marin as a Member of the Italian Board of Directors as of 27th April 2018 in replacement of Daniele Negrato. This appointment follows the previous announcement regarding Michele Marin appointment as CFO of LimaCorporate as of 1st March 2018.

(Logo: https://mma.prnewswire.com/media/637371/Lima_Corporate_Logo.jpg )

After having earned a Business Degree from the Ca' Foscari University of Venice, Michele started his career at PriceWaterhouseCoopers in 1995 and worked in different multinational companies until becoming CFO for Salmoiraghi & Vigano, the Italy-based optical retailer, in 2013. Following the acquisition of the company by Luxottica, he assumed to the role of Chief Accounting Officer for Luxottica in April 2017.

In addition to the functions within the Board of Directors and those as LimaCorporate's group CFO, Michele is in charge of the Legal Affairs and Compliance and the IT departments.
About LimaCorporate

LimaCorporate is a global medical device company providing reconstructive orthopedic solutions to surgeons who face the challenges of improving the quality of life of their patients. Based in Italy, LimaCorporate is committed to the development of innovative products and procedures to enable surgeons to select ideal solution for every individual patient. LimaCorporate's product range includes large joint revision and primary implants and complete extremities solutions including fixation.

For additional information on the Company, please visit: http://www.limacorporate.com
Limacorporate S.p.A.
Via Nazionale, 52
33038 Villanova di San Daniele
Udine - Italy
T: +39-0432-945-511
E: info@limacorporate.com
Source: Limacorporate S.p.A.

Latest Press Release

WCG (WIRB-Copernicus Group) Clinical Services Division Opens Office in Japan

WCG(TM) (WIRB-Copernicus Group(R)) Clinical Services Division, the world's leading provider of solutions that measurably improve the quality and efficiency of clinical research, today announced the opening of the company's new office in Tokyo, Japan....

Head-to-Head Trial Shows Refixia(R) Achieves Greater Total Factor IX Exposure in People With Haemophilia B Than Recombinant Factor IX-Fc Fusion Protein

Adults with haemophilia B who received a single dose Refixia(R) (nonacog beta pegol; N9-GP) achieved greater total factor IX exposure than those treated with rFIXFc (recombinant factor IX-Fc fusion protein). The head-to-head paradigm7 trial also observed...

NovoEight(R) Maintains Potency When Stored at 40?C Offering People With Haemophilia A Increased Flexibility in Their Daily Lives

A new long term stability study has shown that haemophilia A treatment NovoEight(R) (turoctocog alfa) remains potent after three months exposure to temperatures of 40ºC.[1] The results were presented today at the WFH 2018 World Congress in Glasgow,...

The Mall Shopping Center and Government Savings Bank Co-host The Mall Health Beauty Expo 2018

The Mall Shopping Center, Government Savings Bank, leading hospitals and health institutions are co-hosting an annual grand event, "The Mall Health & Beauty Expo 2018" on June 28 – July 4, 2018 at the Grand Hall, G Floor, The Mall Bangkapi....

Merck Data at ASCO 2018 to Showcase Progress and Further Optionality of Oncology Pipeline

ASCO Abstract # ERBITUX(R) (cetuximab): 3521, 3534, e15711; avelumab: 9507, 9537, 9090, 9008, 8563, 3057, 4544, e21531, e13603, e18932, e21623, e21620, e21544; tepotinib (c-Met kinase inhibitor): 9082, 9016; M6620 (ATR inhibitor): 2549, e21048; M3814...

Related Topics